Organotypic models of patient-specific tumours are revolutionizing our understanding of
cancer heterogeneity and its implications for personalized medicine. These advancements …

Wilms tumour (WT) is a childhood embryonal tumour that is paradigmatic of the intersection
between disrupted organogenesis and tumorigenesis. Many WT genes play a critical (non …

Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown
to model clinical response to cancer therapy. However, it remains challenging to use these …

Intratumour heterogeneity (ITH) is a hallmark of cancer that drives tumour evolution and
disease progression. Technological and computational advances have enabled us to …

Cancer is a complex disease in which both genetic defects and microenvironmental
components contribute to the development, progression, and metastasization of disease …

Organoids are in vitro self-assembling, organ-like, three-dimensional cellular structures that
stably retain key characteristics of the respective organs. Organoids can be generated from …

Organoids are self-organizing, expanding 3D cultures derived from stem cells. Using tissue
derived from patients, these miniaturized models recapitulate various aspects of patient …

Recent progress in our understanding of the regulation of epithelial tissue stem cells has
allowed us to exploit their abilities and instruct them to self-organize into tissue-mimicking …

The term “biobanking” is often misapplied to any collection of human biological materials
(biospecimens) regardless of requirements related to ethical and legal issues or the …

Organoid technologies enable the creation of in vitro physiologic systems that model tissues
of origin more accurately than classical culture approaches. Seminal characteristics of these …